Back to search results

RAPID-CKM Study for Type 2 Diabetes and Kidney Disease

This study, called RAPID-CKM, is looking at a new way to help people with type 2 diabetes and kidney disease (chronic kidney disease) get the right treatments. Researchers want to see if an alert in your doctor's electronic health record (Epic system) can help them prescribe important heart and kidney medications (guideline-directed CKM therapies) more often. You could be eligible if you are an adult with type 2 diabetes, receive care at Baylor Scott & White Health, and have a certain level of protein in your urine (confirmed albuminuria). The study will compare patients whose doctors receive these alerts to those whose doctors provide usual care. The main goal is to see if more people start these important medications within 3 months. The study is currently unclear on its recruitment status.

Study design
This is a randomized study involving 600 participants. It compares an Epic-based clinician notification to standard clinical care.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for 3 months to see if they start guideline-directed CKM therapies.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07605390

RAndomized EHR-based Prescribing to Improve Disease-modifying Therapies for Cardio-Kidney-Metabolic Care (RAPID-CKM)

Not Yet Recruiting
NAAges 18+InterventionalTreatment
Baylor Research Institute
~600 participants
Updated 2026-07-20 on ClinicalTrials.gov
What's tested:Epic-Based Clinician NotificationUsual Care

At a glance

Recruiting sites
0 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Initiation of Guideline-Directed Cardio-Kidney Metabolic Therapy
Measured over 3 months
+1 more outcome measured

Conditions

Chronic Kidney Disease
Type 2 Diabetes

Explore related trials

AlbuminuriaChronic Kidney DiseaseMetabolic SyndromeType 2 Diabetes MellitusUrine albumin/creatinine ratio measurement

Where it's being run

2 sites across 1 states
Texas2

Study leadership

  • Shahzeb Khan, MD · PRINCIPAL_INVESTIGATOR · Baylor Scott and White Health

Who to contact

Shahzeb Khan, MD
[email protected]
469-326-2636
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Adults aged ≥18 years
Diagnosis of type 2 diabetes mellitus
Receiving outpatient care within Baylor Scott \& White Health
At least 1 outpatient encounter within the preceding 12 months
Confirmed albuminuria (UACR \>30 mg/g)
Eligible for one or more guideline-directed CKM therapies based on - prespecified clinical criteria and EHR review

Exclusion

Type 1 diabetes mellitus
Contraindication or documented intolerance to all eligible guideline-directed CKM therapies
Advanced kidney dysfunction below recommended initiation thresholds for SGLT2i or finerenone
Hyperkalemia or elevated baseline serum potassium precluding safe therapy initiation
Contraindicated drug interactions (e.g., strong CYP3A inhibitors with finerenone)
Other guideline- or labeling-based contraindications to therapy initiation

What this trial measures

  • Initiation of Guideline-Directed Cardio-Kidney Metabolic Therapy3 months

    Proportion of eligible participants newly prescribed one or more guideline-directed cardio-kidney-metabolic (CKM) therapies, including renin-angiotensin system inhibitors (RASi), sodium-glucose cotransporter-2 inhibitors (SGLT2i), non-steroidal mineralocorticoid receptor antagonists (ns-MRA), or glucagon-like peptide-1 receptor agonists (GLP-1RA) as assessed using electronic health record (EHR) data.

  • Therapy-Specific Initiation Rate3 months

    Proportion of participants eligible for a specific CKM therapy who were newly prescribed each individual guideline-directed CKM therapy class (RASi, SGLT2i, ns-MRA, or GLP-1RA), as assessed using electronic health record (EHR) data.